Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Chemotherapy via Ommaya Reservoir for HER2- Breast Cancer with Leptomeningeal Metastasis
NCT06230055Phase 4Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate, thiotepa, cytarabine, liposomal cytarabine, pemetrexed and 1 more in leptomeningeal metastasis (LM) and breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Neural Progression-Free Survival. Started Jan 2024; status: recruiting.
02
Drugs
methotrexatethiotepacytarabineliposomal cytarabinepemetrexed
03
Conditions
leptomeningeal metastasis (LM)breast cancer
Beyond the preview
Go deeper on NCT06230055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06230055.